Biosimilar Clinical Development

Scientific Considerations and New Methodologies

By: Kerry B. Barker (Editor), Sr., Ralph B. D'Agostino (Editor), Siyan Xu (Editor), Sandeep M. Menon (Editor), PhD, Bo Jin (Editor)

Write A Review

Hardcover | 17 January 2017 | Edition Number 1

Sorry, we are not able to source the book you are looking for right now.

We did a search for other books with a similar title, however there were no matches. You can try selecting from a similar category, click on the author's name, or use the search box above to find your book.

Biosimilars have the potential to change the way we think about, identify, and manage health problems. They are already impacting both clinical research and patient care, and this impact will only grow as our understanding and technologies improve. Written by a team of experienced specialists in clinical development, this book discusses various potential drug development strategies, the design and analysis of pharmacokinetics (PK) studies, and the design and analysis of efficacy studies.

Industry Reviews

"Thus, the book Biosimilar Clinical Development contains five chapters discussing general issues involving biosimilars. The remaining six chapters present statistical methods, many of which are new, and their applications in bioequivalence and biosimilarity studies; they are really research papers. . . It will appeal to readers interested in biosimilars and especially in their statistical assessments."
~Laszlo Endrenyi, University of Toronto

"The book is edited by a team of renowned experts from both statistics and biosimilar clinical development. It contains 11 chapters, covering not only statistical issues but also pre-clinical and clinical development issues not regularly discussed on this kind of book, as well as references to regulatory considerations of upmost importance for statisticians working in the strongly regulated environment of clinical development . . . I strongly recommend the reading of this book. In my opinion, the book should be a must-have reading for professionals who work regularly with biosimilars and want to have an overview of state-of-the art methods for 'hot-topics' in the analysis and planning of clinical trials for this purpose."
~David Manteigas

"Thus, the book Biosimilar Clinical Development contains five chapters discussing general issues involving biosimilars. The remaining six chapters present statistical methods, many of which are new, and their applications in bioequivalence and biosimilarity studies; they are really research papers. . . It will appeal to readers interested in biosimilars and especially in their statistical assessments."
~Laszlo Endrenyi, University of Toronto

"The book is edited by a team of renowned experts from both statistics and biosimilar clinical development. It contains 11 chapters, covering not only statistical issues but also pre-clinical and clinical development issues not regularly discussed on this kind of book, as well as references to regulatory considerations of upmost importance for statisticians working in the strongly regulated environment of clinical development . . . I strongly recommend the reading of this book. In my opinion, the book should be a must-have reading for professionals who work regularly with biosimilars and want to have an overview of state-of-the art methods for 'hot-topics' in the analysis and planning of clinical trials for this purpose."
~David Manteigas

Shipping

	Standard Shipping	Express Shipping
Metro postcodes:	$9.99	$14.95
Regional postcodes:	$9.99	$14.95
Rural postcodes:	$9.99	$14.95

Orders over $79.00 qualify for free shipping.

How to return your order

At Booktopia, we offer hassle-free returns in accordance with our returns policy. If you wish to return an item, please get in touch with Booktopia Customer Care.

Additional postage charges may be applicable.